Premaitha talks of 'strong' momentum following patent dispute resolution

25th Oct 2018 10:23

(Sharecast News) - Investors in molecular diagnostics company Premaitha Health were told on Thursday how the group's positive momentum had continued into the second half of its financial year.The AIM-traded firm had reported strong commercial progress in the first half, with 45% revenue growth.Non-executive chairman Adam Reynolds said it was "very positive" that the strong momentum had continued into the second half."The recent resolution of the patent litigation was a significant milestone for the group, and will enable us to open up new territories, which historically were inaccessible," Reynolds was set to tell shareholders."As part of our commercial expansion strategy we aim to deliver a wider portfolio of content and I am confident that we have both the technical capability and industry reach to deliver additional products across multiple platforms as we transition towards a platform agnostic model."With the fundraising now completed, a refreshed brand identity and a strengthened management team in place, I have considerable confidence in the group's ongoing prospects."